Clinical Trial Update: Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating biomarkers predicting response to sirolimus plus chemotherapy in high-risk acute myeloid leukemia; trial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED